These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12870783)

  • 1. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.
    Hur C; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2003 Jul; 48(7):1273-83. PubMed ID: 12870783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
    Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
    Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
    Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
    Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus.
    Hur C; Wittenberg E; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2005 Jan; 50(1):116-25. PubMed ID: 15712648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with various Barrett's esophagus associated health states.
    Hur C; Wittenberg E; Nishioka NS; Gazelle GS
    Health Qual Life Outcomes; 2006 Aug; 4():45. PubMed ID: 16884539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Hur C; Nishioka NS; Gazelle GS
    J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
    Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
    Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus.
    Filby A; Taylor M; Lipman G; Lovat L; Haidry R
    J Comp Eff Res; 2017 Jul; 6(5):425-436. PubMed ID: 28541099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review.
    Sánchez A; Reza M; Blasco JA; Callejo D
    Dis Esophagus; 2010 Nov; 23(8):633-40. PubMed ID: 20545970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Esophagectomy Versus Endoscopic Treatment for Esophageal High-grade Dysplasia.
    Hu Y; Puri V; Shami VM; Stukenborg GJ; Kozower BD
    Ann Surg; 2016 Apr; 263(4):719-26. PubMed ID: 26672723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.
    Prasad GA; Wang KK; Buttar NS; Wongkeesong LM; Krishnadath KK; Nichols FC; Lutzke LS; Borkenhagen LS
    Gastroenterology; 2007 Apr; 132(4):1226-33. PubMed ID: 17408660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.
    Gordon LG; Hirst NG; Mayne GC; Watson DI; Bright T; Cai W; Barbour AP; Smithers BM; Whiteman DC; Eckermann S;
    J Gastrointest Surg; 2012 Aug; 16(8):1451-61. PubMed ID: 22644445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.